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Identity 
Other names: BMP2B, BMP2B1, MCOPS6, OFC11, 
ZYME 
HGNC (Hugo): BMP4 
Location: 14q22.2 
Local order: Genes flanking BMP4 at 14q22.2 are 
(centromeric to telomeric): MIR5580 (microRNA 
5580), BMP4, ATP5C1P1 (ATP synthase, H+ 
transporting, mitochondrial F1 complex, gamma 
polypeptide 1 pseudogene 1).
DNA/RNA 
Description 
Gene spans approximately 9 kbp on the minus strand at 
14q22.2. 
Transcription 
Alternative splicing in the 5'UTR gives rise to 3 
transcript variants, all encoding an identical protein. 
Transcript variant 1 is 1917 bp in length with 4 exons 
(2 coding exons), transcript variant 2 is 1708 bp in 
length with 4 exons (2 coding exons), and transcript 
variant 3 is 1705 bp in length with 3 exons (2 coding 
exons).  
In Xenopus embryos, BMP4 itself, along with the 
homeobox genes Vox, X-vent1, X-vent2, GATA-1, 
GATA-2 and AP-1 were found to induce the expression 
of BMP4 and control dorsoventral patterning in the 
mesoderm (Jones et al., 1992; Kim et al., 1998; 
Onichtchouk et al., 1996; Schmidt et al., 1996), 
whereas organizer signals, chordin and noggin, and X-
lim1 negatively regulate BMP4 transcription (Kim et 
al., 1998). Lung specification in Xenopus depends on 
the suppression of BMP4 expression by zinc-finger 
transcriptional repressors Osr1 and Osr2 (Rankin et al., 
2012). 
Analysis of the mouse BMP4 gene identified 2 G-C 
rich Sp1 binding motifs proximal to the transcriptional 
start sites for exons I and II (Kurihara et al., 1993). The 
presence of dual promoter regions flanking exons I and
II were later confirmed in human cancer cell lines (van 
den Wijngaard et al., 1996). Mouse BMP4 is negatively 
regulated by direct binding of chicken ovalbumin 
upstream-transcription factor I (COUP-TF1) to the 
proximal promoter of exon I (Feng et al., 1995). 
Deletion analysis of the mouse BMP4 promoter in 
MC3T3E1 cells identified a cis-acting E-box element 
proximal to the transcriptional start site that is bound 
by upstream regulatory factor (USF), a member of the 
helix-loop-helix family of regulatory proteins (Ebara et 
al., 1997). In mouse development, GATA-4 and -
GATA-6 were found to specifically regulate BMP4 
transcription to mediate endoderm-mesoderm 
signalling and early vasculogenesis (Nemer et al., 
2003).  
Similarly, analysis of mouse embryonic stem cells 
identified the transcriptional corepressor Bcor as an 
important regulator of ES cell differentiation into 
mesoderm, ectoderm and hematopoietic lineages 
through regulating developmental genes including 
BMP4 expression (Wamstad et al., 2008). Furthermore, 
the transcription factor Cdx2 has been shown to 
directly regulate BMP4 expression in mouse 
trophoblast cells to promote early mouse 
embryogenesis (Murohashi et al., 2010), while Shox2 
regulates BMP4 expression to promote pacemaker 
development in the murine heart (Puskaric et al., 2010). 
Analysis of the human BMP4 promoter in U2OS and 
SaOS2 cells identified the lack of a proximal TATA 
box, while sharing similar transcriptional start site  and 
regulatory elements with the mouse BMP4 promoter 
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(Helvering et al., 2000; Shore et al., 1998). Putative 
binding motifs for AP1, Sp1, CRE, Cfab1 were 
identified, and direct binding of Cfab1 to the BMP4 
promoter was confirmed, along with transcriptional 
upregulation of BMP4 by osteogenic compounds such 
as retinoic acid and the phorbol ester PMA (Helvering 
et al., 2000). 
Transcriptional control of BMP4 is also important i 
diseased states. During recovery from acute anemia, 
hypoxia induces BMP4 expression and subsequent 
erythropoiesis in the murine spleen through direct 
binding of HIF2alpha to the BMP4 promoter (Wu et 
al., 2010). In retinal pigment epithelium cells of 
patients suffering from the wet form, but not the dry 
form, of macular degeneration, TNFalpha represses 
BMP4 transcription through phosphorylation of the 
transcription factor Sp1, demonstrating a BMP4 
expression-dependent molecular switch (Xu et al., 
2011).  
In hepatocellular carcinoma cells, Ets-1 was 
demonstrated to directly regulate hypoxia-induced 
BMP4 transcription to promote tumorigenesis 
(Maegdefrau et al., 2009). In colorectal cancer cells, 
oncogenic KRAS can repress BMP4 expression 
through a novel ras-responsive region (Duerr et al., 
2012).  
In addition to many proximal regulatory sites, the 
BMP4 gene, along with many other BMP family genes, 
resides within a conserved gene desert, which contains 
many additional distal cis-regulatory regions (located 
over 30 kbp from coding sequences) that control BMP4 
expression in a spatiotemporal and tissue-dependent 
manner (Chandler et al., 2009; Pregizer et al., 2009). 
For example, an evolutionarily conserved distal 
enhancer site, 46 kb upstream of the transcriptional 
start site, is bound by Pitx2 and likely participates in 
tooth and limb morphogenesis (Jumlongras et al., 
2012). Furthermore, a common polymorphism found 
within the distal BMP4 promoter (17kb upstream) acts 
as a cis-acting enhancer of BMP4 transcription, and is 
significantly associated with colorectal cancer risk 





BMP4, a member of the TGFbeta superfamily of 
signalling molecules, is a 46.5 kDa, 408 aa protein that 
is translated as a precursor containing a signal peptide 
(aa 1 - 19), a prodomain (aa 20 - 292) and a mature 
domain (aa 293 - 408).  
After the BMP signal peptide has been removed, 
dimerization of the proproteins proceeds.  
Proprotein cleavage is achieved by the candidate serine 
endoproteases Furin, PCSK5, PCSK6, or PCSK7 at the 
consensus sequence RXXR, resulting in the generation 
and secretion of biologically active molecules (Bragdon 
et al., 2011; Cui et al., 1998; Goldman et al., 2006; 
Shimasaki et al., 2004). As with other TGFbeta family 
members, BMP4 is a cysteine knot-containing, 
disulfide-linked dimer (Jones et al., 1994; Shimasaki et 
al., 2004), containing a conserved TGF-beta propeptid  
domain (pfam00668) and transforming growth factor 
beta like domain (cl02510). One high-throughput study 
has identified a ubiquitination site at Lys-185 (Kim et 
al., 2011). 
Expression 
The amino acid sequence for BMP4 was first derived 
from an isolated preparation of bovine bone (Wozney 
et al., 1988). Human BMP4 was cloned from a 
placental cDNA library (Oida et al., 1995). Apart from 
its high expression in developing embryonic tissues 
(Chen et al., 2004), BMP4 was determined by 
microarray analysis to be highly expressed in adult 
tissues such as the thymus, spleen, brain, heart, muscle, 
kidney, lung, liver, pancreas, and prostate (Schmueli et 
al., 2003; Yanai et al., 2005).  
Immunohistochemical analysis of adult tissues shows 
high expression in epithelial cells of the skin, bladder 
and stomach (Alarmo et al., 2012). In tumors, BMP4 is 
expressed in melanoma, ovarian, gastric, basal cell,
renal and squamous carcinomas of the head and neck 
(Chiu et al., 2012; Deng et al., 2007; Davies et al., 
2008; Giacomini et al., 2006; Johnson et al., 2009; Kim 
et al., 2011; Kwak et al., 2007; Laatio et al., 2011; 
Lombardo et al., 2011; Sneddon et al., 2006; 
Rothhammer et al., 2005; Xu et al., 2011). 
Overexpression of BMP4 in comparison to normal 
tissues is observed in breast, ovarian, gastric, 
hepatocellular and colorectal carcinomas (Alarmo et 
al., 2012; Chiu et al., 2012; Deng et al., 2007; Kim et 
al., 2011). 
Localisation 
BMP4 is a secreted protein localized within the 
extracellular milieu (Chen et al., 2004), but has also 
been shown to localize within the cytoplasm in vesicl  
directed for lysosomal degradation, in order to tightly 
mitigate BMP4 signalling (Kelley et al., 2009). 
Function 
BMP4 is a member of the bone morphogenetic protein 
family, which is part of the transforming growth factor-
beta superfamily of growth and differentiation factors.  
Bone morphogenetic proteins were originally identified 
by an ability of demineralized bone extract to induce 
endochondral osteogenesis in vivo in an extraskeletal 
site (Urist, 1965), but are now considered essential 
factors with varying roles during embryogenesis, 
skeletal formation, hematopoiesis and neurogenesis 
(Bragdon et al., 2001; Chen et al., 2004; Kallioniemi, 
2012). In adult tissues, BMP4 signalling can control 
many cellular behaviours including differentiation, 
proliferation, apoptosis, and motility (Kallioniemi, 
2012).  
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The mature BMP4 dimer binds to type I and II serine-
threonine kinase receptors, and the constitutively active 
BMP type II receptor will phosphorylate the type I 
receptor upon ligand binding (Miyazono et al., 2010; 
Nohe et al., 2004). The activated type I BMP receptor 
is then able to phosphorylate the cytosolic receptor-
regulated SMAD proteins (Attisano et al., 2000; 
Bragdon et al., 2001; Miyazono et al., 2010), which 
will then form a complex with the common SMAD4, 
translocate to the nucleus to regulate gene transcription 
(Feng et al., 2005; ten Dijke et al., 2003). In addition to 
this canonical SMAD-dependent signaling pathway, 
BMP4 can signal through SMAD-independent means 
to directly induce ERK and p38 MAPKs, JNK, NFkB, 
PI3K, PKA, PKC and PKD signaling pathways 
affecting cell survival, apoptosis, migration and 
differentiation (Bragdon et al., 2011). In addition to 
intracellular regulation, BMP4 signals can be 
modulated at the receptor level through interaction with 
three different type I (BMPR1A [ALK3], BMPR1B 
[ALK6], and ACVR1A [ALK2]) and type II (BMPR2, 
ACVR2A [Act-RII], and ACVR2B [Act-RIIB]) 
receptors (Kawabata et al., 1998; Miyazono et al., 
2010; Nohe et al., 2004), and negatively regulated by 
interaction with the pseudoreceptor BAMBI 
(Onichtchouk et al., 1999). BMP4 signalling can also 
be regulated at the extracellular level through binding 
to the endogenous inhibitors tsg (Twisted gastrulation) 
and Follistatin, and those belonging to the Dan family 
(Dan, Gremlin, Gremlin2, Cerberus, Coco, Caronte, 
Ectodin, and Sclerostin), and the Chordin family 
(Chordin, Chordin-like-2, Noggin) of BMP antagonists 
(Bragdon et al., 2011). 
Homology 
There are BMP4 homologs in several vertebrate 
species, including chimpanzee, rhesus monkey, dog, 
cow, chicken, rat, mouse, lizard, frog (Xenopus laevis), 
and zebrafish (Danio rerio) and in invertebrates such as 




Heterozygous mutations in exons 3 and 4 of the BMP4 
gene resulting in decreased expression were found in 
children with cleft lip and cleft palate (Suzuki et al., 
2009), including: a 1037C-T transition resulting in a  
A346V substitution; a 271A-T transversion resulting  
a S91C substitution; a 860G-A transition resulting in an 
R287H substitution; and a 592C-T transition resulting 
in an R198X substitution. 
Three pathogenic germline mutations were identified in 
a cohort of 504 genetically enriched colorectal cancer 
cases. p.R286X (g.8330C>T) localizes to the N-
terminal of the prodomain truncating the protein prior 
to the active domain; p.W325C (g.8449G>T) and 
p.C373S (g.8592G>C) mutations are predicted from 
protein homology modelling with BMP2 to impact 
deleteriously on BMP4 function; and p.C373S 
(g.8592G>C) segregates with adenoma and 
hyperplastic polyps in first-degree relatives, suggesting 
this germline mutation may confer a juvenile 
polyposis-type phenotype (Lubbe et al., 2011). 
Somatic 
Four substitution missense mutations have been 
identified: two mutations were detected in two different 
single prostate tumors (c.344A>T, p.N115I (Grasso et 
al., 2012), c.857G>A, p.R286Q (Barbieri et al., 201), 
and two in two different large intestinal carcinoma 
tumors (c.631C>T, p.R211W, and c.1222C>T, 
p.R408C)) (The Cancer Genome Atlas Network, 2012). 
Implicated in 
Fibrodysplasia ossificans progressiva 
(FOP) 
Prognosis 
Fibrodysplasia ossificans progressiva (FOP) is an 
extremely rare and disabling autosomal dominant 
genetic disorder with complete penetrance 
characterized by congenital malformations of the grat 
toes and by progressive heterotopic endochondral 
ossification in predictable anatomical patterns. Ectopi  
expression of BMP-4 was found in FOP patients 
(Gannon et al., 1997; Xu et al., 2000). 
Cytogenetics 
Overexpression of BMP4 mRNA was found in FOP 
patients (Shafritz et al., 1996), in addition a 
heterozygous activating mutation found in the ACVR1 
gene (Shore et al., 2006). 
Microphthalmia, syndromic 6 (MCOPS6) 
Prognosis 
A loss of BMP4 expression can lead to the heritable 
disorder microphthalmia syndromic type 6 (MCOPS6); 
also known as microphthalmia and pituitary anomalies 
or microphthalmia with brain and digit developmental 
anomalies. Microphthalmia is a clinically 
heterogeneous disorder of eye formation, ranging from 
small size of a single eye to complete bilateral absence 
of ocular tissues (anophthalmia). MCOPS6 is 
characterized by microphthalmia/anophthalmia 
associated with facial, genital, skeletal, neurologic and 
endocrine anomalies. (Bakrania et al., 2008; Bennett et 
al., 1991; Elliott et al., 1993; Lemyre et al., 1998; 
Phadke et al., 1994). 
Cytogenetics 
Deletions in 14q22-q23 are associated with 
anophthalmia-microphthalmia, brain, pituitary, and ear 
anomalies including structural defects and hearing loss, 
hypothyroidism, poly- and/or syndactyly, clinodactyly, 
high arched palate, cryptorchidism, and developmental 
delay (Ahmad et al., 2003; Bennett et al., 1991). 
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Oral Facial Cleft 11 (OFC11) 
Prognosis 
Mutations in the BMP4 gene during development can 
result in congenital 'healed' cleft lip (CHCL), an 
unusual heritable anomaly consisting of a paramedian 
'scar' of the upper lip with an appearance suggesting 
that a typical cleft lip was corrected in utero. The 
CHCL is frequently associated with an ipsilateral notch 
in the vermilion border and a 'collapsed' nostril 
(Castilla et al., 1995). 
Cytogenetics 
Missense and nonsense mutations in the BMP4 gene 
resulting in decreased expression were found in 




BMP4 treatment of primary cultures of basal carcinoma 
cells reduces cell growth and induces the expression of 
keratinocyte differentiation markers, which can be 
antagonized by the BMP inhibitor gremlin1 (Sneddon 
et al., 2006). 
Bladder cancer 
Oncogenesis 
BMP4 inhibits growth in the RT4 cell line, but no 
effect is seen in TCC-Sup or TSU-Pr1 cells; expression 
of BMPR2 in TSU-Pr1 cells restores the growth-
inhibitory effect of BMP4 treatment in nude mice (Kim 
et al., 2004). Through the mining of publicly available 
whole genome microarray datasets, BMP4 was 
identified within a set of 17 differentially expressed 
genes to be downregulated in bladder cancers 
(Zaravinos et al., 2011). 
Brain cancers 
Oncogenesis 
BMP4 increased growth and reduced apoptosis of the 
neuroectodermal tumor cell line DAOY (Iantosca et al., 
1999). Treatment of glioblastoma stem cells with 
BMP4 decreased proliferation and induced 
differentiation in GBM cells (Piccirillo et al., 2006), 
cerebellar granule neuron progenitors (GNPs) and 
primary GNP-like medulloblastoma cells (Zhao et al.,
2008), and inhibited glioma stem cell proliferation via 
G1 arrest and CCND1 while enhancing apoptosis 
through induction of Bax and inhibition of Bcl-2 and 
Bcl-xL (Zhou et al., 2011). BMP4-dependent growth 
inhibitory effects were also seen in the brain glioma 
cell line U251 (Liu et al., 2011). BMP4 is expressed in 
meningiomas, and stimulates the proliferative capacity 
of primary meningioma cell cultures via 
phosphorylation of Smad 1, but not p38 MAPK 
(Johnson et al., 2009). Human astrocytomas were found 




BMP4 is highly expressed in primary breast cancer 
tumors and cell lines (Alarmo et al., 2007), and strong 
immunohistochemical expression of BMP4 correlates 
significantly with reduced proliferation and increas d 
rates of recurrence (Alarmo et al., 2012). Methylation 
of the BMP4 promoter, combined within a four-gene 
methylation signature, was found predictive of outcme 
in steroid receptor-positive, node-negative, HER-2 
negative breast cancer patients treated with 
anthracycline (Hartmann et al., 2009). 
Oncogenesis 
Exogenous treatment of BMP4 abrogates lumen 
formation in mammary epithelial cells and promotes 
invasive growth (Montesano, 2007). BMP4 treatment 
did not affect the proliferative capacity of immortalized 
mammary epithelial cells, however BMP4 potentiates 
growth factor-induced proliferation (Montesano et al.,
2008). BMP4 treatment of MDA-MB-231 and MCF-7 
breast carcinoma cells inhibited MMP expression and
activity, decreasing their metastatic potential (Shon et 
al., 2009). In nine breast cancer cell lines, BMP4 
treatment induced growth suppression via G1 arrest, 
while stimulating cell migration and invasion in a 
SMAD-dependent manner (Ketolainen et al., 2010). 
BMP4 treatment of MDA-MB-231 and MCF-7 breast 
cancer cell lines induced migration and invasion 
phenotypes via the upregulation of MMP-1 and 
CXCR4 that could be abrogated by either anti-BMP4 
siRNA or Noggin treatment (Guo et al., 2012). BMP4 
treatment of multiple breast cancer cell lines and 
analysis using a whole genome oligo microarray 
revealed a strong transcriptional response for genes 
involved in cellular differentiation and transcriptional 
activity (Rodriguez-Martinez et al., 2011). 
Colorectal carcinoma (CRC) 
Prognosis 
Three germline pathogenic mutations of BMP4, 
p.R286X (g.8330C>T), p.W325C (g.8449G>T) and 
p.C373S (g.8592G>C) were suggested to be causal for 
colorectal cancer (Lubbe et al., 2011). Three common 
variants (rs4444235, rs17563, and rs1957636) at the 
BMP4 locus have been associated with elevated risk of 
colorectal cancer (Houlston et al., 2008; Lubbe et al., 
2012; Slattery et al., 2012; Theodoratou et al., 2012; 
Tomlinson et al., 2011). Immunohistochemical and 
real-time mRNA expression analysis of BMP4 in 
primary tumors correlated strongly with advanced stage 
and liver metastases (Deng et al., 2007). 
Oncogenesis 
Germline BMP4 mutations were found to be 
deleterious to the BMP4 protein in colorectal cancers 
(Lubbe et al., 2011). Furthermore, a common 
polymorphism found within the distal BMP4 promoter 
(17 kb upstream) acts as a cis-acting enhancer of BMP4  
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transcription, leading to enhanced expression, which is 
significantly associated with colorectal cancer risk 
(Lubbe et al., 2012).  
Overexpression of BMP4 in HCT116 human colorectal 
cancer cell line promotes in vitro migration and 
invasion (Deng et al., 2007). In colorectal stem cells 
isolated from primary tumors, BMP4 treatment induced 
terminal differentiation, apoptosis and 
chemosensitization in vitro and in tumour xenografts 
(Lombardo et al., 2011). BMP4 signalling has been 
shown to protect HCT116 cells from heat-induced 
apoptosis by modulating MAPK pathways (Deng et al., 
2007), and overexpression of BMP4 can enhance the 
invasiveness of CRC cells independent of Smad4 
activity (Deng et al., 2009). 
Gastric cancer (GC) 
Prognosis 
Expression of BMP4 is inversely related to prevalence 
of lymph node metastasis in gastric adenocarcinomas 
(Kim et al., 2011). BMP4 mRNA was significantly 
overexpressed in gastric cancers relative to mucosal 
controls and negatively correlated with BMP4 promoter 
methylation, while high expression of BMP4 predicted 
poor outcome (Ivanova et al., 2012). 
Oncogenesis 
Immunocytochemical analysis of primary gastric 
tumors revealed that BMP4 was significantly 
overexpressed in comparison to normal mucosa, and 
correlated with Helicobater pylori infection. However, 
the expression of BMP4 negatively correlated with the
presence of lymph node metastases and tumor 
invasiveness (Kim et al., 2011). BMP4 is highly 
expressed in cisplatin-resistant cell lines, and 
overexpression induced GC cell line tumorigenicity in 
vitro, while shRNA-mediated knockdown decreased 
proliferation, colony formation and restored cisplatin 
sensitivity (Ivanova et al., 2012). In diffuse-type gastric 
carcinoma cells lines in vitro, BMP4 acted as a tumor 
suppressor by inducing cell cycle arrest in these cells 
via p21 induction through the SMAD pathway (Shirai 
et al., 2011). 
Hepatocellular carcinoma (HCC) 
Prognosis 
BMP4 is significantly overexpressed in 60% of primary 
HCC tumors (Chiu et al., 2012). BMP4 
immunohistochemical expression significantly 
correlated with increased tumor nodules, increasing 
TMN stage, vascular invasion and tumor invasiveness, 
and was an independent predictor of disease-free and 
overall survival in HCC patients (Guo et al., 2012). 
Oncogenesis 
BMP4 promotes the growth and migration of HCC cell 
lines in vitro, and BMP4 can induce cyclin-dependent 
kinase 1 (CDK1) and cyclin B1 upregulation to 
accelerate cell-cycle progression and metastasis in 
HCC cells through MEK-ERK signaling (Chiu et al., 
2012).  
In HCC cell lines, BMP4 expression was shown to be 
induced by hypoxia to promote in vitro migration, 
invasion, anchorage-independence and tube formation 




Combined with 3 other biomarkers, 
immunohistochemical expression of BMP4 was shown 
to predict the risk of bone metastasis in stage III 
resected non-small cell lung carcinoma (Zhou et al., 
2012). 
Oncogenesis 
Treatment of lung cancer cell line A549 with BMP4 
induced a senescent phenotype, characterized by 
reduced growth, increased size, reduced invasion, and 
expression of senescence-associated beta-galactosidase. 
BMP4-treated A549 cells also exhibited decreased 
growth in mouse xenograft models (Buckley et al., 
2004). BMP4 via Smad signalling has also been shown 
to mediate adriamycin-induced premature senescence 
in multiple lung carcinoma cell lines (Su et al., 2009). 
A later study found that cooperativity between p38 
MAPK and Smad pathways is required for BMP4-
induced senescence (Su et al., 2011). 
Melanoma 
Prognosis 
Bioinformatics analyses identified polymorphisms 
within the BMP4 gene (SNPs 6007 C/T (rs17563) and 
3445 T/G (rs4898820)) affecting mRNA expression 
and shows a significant association with cutaneous 
melanoma (Capasso et al., 2009). 
Oncogenesis 
BMP4 was found to be overexpressed in melanoma cell 
lines, and primary and metastatic melanomas compared 
to nevi. Although no effect was seen on proliferation, 
BMP4 signalling significanctly increased migration a d 
invasion in melanoma cell lines (Rothhammer et al., 
2005). BMP4 was later shown to stimulate 
angiogenesis in malignant melanomas by inducing tube
formation as well as the migratory efficiency of 




BMP4 inhibited DNA synthesis and induced G1 arrest 
and/or apoptosis in OH-2, IH-1 and ANBL-6 cell lines 
(Hjertner et al., 2001), and induced apoptosis in 
multiple myeloma cell lines via Smad-dependent down-
regulation of MYC (Holien et al., 2012).  
However, BMP4 was shown to be overexpressed in 
bone marrow cells derived from multiple myeloma  
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patients, and partially protected myeloma cells from 
apoptosis induced by the anti-myeloma drug 




One study identified via immunohistochemistry that 
high BMP4 expression in primary serous ovarian 
cancer tumors was an independent prognostic factor for 
longer progression-free survival time and overall 
survival prior to administration of chemotherapy 
(Laatio et al., 2011). 
Oncogenesis 
An autocrine BMP signalling pathway was identified n 
primary human ovarian surface epithelial cells and 
primary ovarian cancer cells. Treatment of primary 
ovarian cancer cells with BMP4 had no effect on 
proliferative capacity, but long-term cultures showed 
decreased cell density and increased cell spreading and 
adherence (Shepherd et al., 2003).  
Treatment of primary ovarian cancer cells with 
exogenous BMP4 produced morphological alterations 
and increased cellular adhesion, motility and invasion, 
which could be inhibited by Noggin, while primary 
ovarian surface epithelial cells showed no response to 
these ligands (Thériault et al., 2007). BMP4 treatment 
also altered the EMT markers Snail, Slug and E-
cadherin, along with an increase in activation of Rho-
GTPases, suggesting that ovarian cancer agressive 
cellular behaviours may be mediated through autocrine 
BMP4 signalling (Thériault et al., 2007). These BMP4-
induced changes in cellular morphology and motility 
were later found to be Smad-dependent (é et al., 2011). 
Ovarian cancer tumor-associated mesenchymal stem 
cells were found to have overexpression of BMP4, 
suggesting BMP4 may have a role in modulation of the 
tumor microenvironment to promote tumorigenesis 
(McLean et al., 2011). 
Pancreatic cancer 
Cytogenetics 
A CGH study of pancreatic primary tumors, cell lines 
and xenografts determined a significant recurrent low-
level gain of chromosome 14q22.2 in these samples 
(Nowak, et al., 2005). 
Oncogenesis 
BMP4 demonstrates overexpression at the mRNA level 
in 25% of 16 established pancreatic cell lines compared 
to normal tissues. Treatment of 5 cell lines with BMP4 
induced growth suppression via G1 arrest, but 
significantly increased the migratory and invasive 
phenotypes of pancreatic cell lines (3 out of 5) in vitro 
via SMAD-dependent signalling (Virtanen et al., 2011).  
BMP4 treatment of Panc-1 cells induced an EMT 
response characterized by increased migration 
mediated by MSX2 induction (Hamada et al., 2007), 
while another study demonstrated BMP4 treatment of 
Panc-1 cells also resulted in an EMT response 
involving MMP2 activity that was Smad1-dependent 
(Gordon et al., 2009). 
Prostate cancer 
Prognosis 
Immunohistochemical analysis of primary prostate 
cancer tumors and bone metastases revealed that BMP4 
was overexpressed in the metastatic deposits, but not 
the primary tumors suggesting a role for BMP4 
expression in promoting prostate cancer metastasis 
(Spanjol et al., 2010). 
Oncogenesis 
Treatment of LNCaP cells with BMP4 inhibited 
proliferation through G1 arrest and induction of p21, 
however no effect on growth was seen in PC-3 cells 
(Brubaker et al., 2004).  
Another study confirmed the growth inhibitory effect 
of BMP4 on LNCaP cells and found the effect could be 
abrogated by Noggin treatment (Shaw et al., 2010).  
In LAPC-4 cells, BMP4 treatment showed no effect on 
cellular proliferation, migration or invasion (Feely et 
al., 2005).  
However a later study found that BMP4 could promote 
prostate tumor growth in bone through osteogenesis in 




BMP4 has cell-type specific effects on pituitary cells 
(Labeur et al., 2010). BMP4 signalling was determined 
to stimulate proliferation and MYC expression in 
pituitary prolactinomas but not in other pituitary 
tumors, along with promoting tumorigenic growth of 
rat GH3 cells in nude mice (Paez-Pereda et al., 2003). 
BMP4 expression is reduced in corticotrophinomas 
from Cushing's  
 
patients in comparison to normal corticotroph cells, 
while BMP4 treatment of mouse AtT-20 corticotroph 
cells showed no effect on proliferation, but transfection 
of the BMP4 inhibitor Noggin stimulated tumorigenic 
growth in nude mice (Giacomini et al., 2006). 
Renal cell carcinoma (RCC) 
Prognosis 
Immunohistochemical analysis of RCC tumors 
demonstrated BMP4 overexpression in 44%, however 
no prognostic value could be associated with BMP4 
expression (Kwak et al., 2007). BMP4 mRNA 
expression was significantly higher in non-clear cell 
RCCs than clear cell RCCs, however no association of 
BMP4 expression with survival was found (Markic et 
al., 2011). 
Oncogenesis 
The BMP4 promoter was hypermethylated, resulting in 
downregulated expression in 35% of primary RCC 
tumors tested (Ricketts et al., 2012). 
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Retinoblastoma 
Oncogenesis 
BMP4 signalling was intact, and exogenous treatment 
increased caspase-independent apoptosis in the RB1-
deficient cell line WERI-Rb1, while no effect on 
proliferation was seen (Haubold et al., 2010). 
Various cancers 
Note 
Numerous microarray studies indexed in Oncomine 
(oncomine.org) document altered expression of BMP4 
in other cancers, including head and neck cancers, 
cervical cancers and lymphomas and sarcomas. 
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